--- title: "Phio Pharmaceuticals | 8-K: FY2026 Q2 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/295144507.md" datetime: "2026-08-06T21:11:49.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295144507.md) - [en](https://longbridge.com/en/news/295144507.md) - [zh-HK](https://longbridge.com/zh-HK/news/295144507.md) --- # Phio Pharmaceuticals | 8-K: FY2026 Q2 Revenue: USD 0 Revenue: As of FY2026 Q2, the actual value is USD 0. EPS: As of FY2026 Q2, the actual value is USD -0.36. EBIT: As of FY2026 Q2, the actual value is USD -4.138 M. #### Cash Position As of June 30, 2026, Phio Pharmaceuticals Corp. reported cash and cash equivalents of $12.996 million, a decrease from $21.031 million at December 31, 2025. #### Research and Development Expenses For the three months ended June 30, 2026, research and development expenses were $3.082 million, an increase of $2.0 million or 187% compared to $1.074 million for the same period in 2025, primarily due to a $0.9 million rise in nonclinical toxicology study costs and a $1.5 million increase in CMC costs, partially offset by a $0.3 million decrease in clinical trial costs.For the six months ended June 30, 2026, these expenses were $5.874 million, marking an increase of $3.9 million or 200% from $1.960 million in the prior year period, mainly driven by a $1.8 million increase in nonclinical toxicology study costs, a $1.5 million increase in CMC costs, and a $0.9 million increase in consulting, patent, and employee-related costs, partially offset by a $0.3 million decrease in clinical trial costs. #### General and Administrative Expenses General and administrative expenses for the three months ended June 30, 2026, decreased by $49 thousand or 4% to $1.186 million, from $1.235 million in the comparable period of 2025.For the six months ended June 30, 2026, these expenses increased by $340 thousand or 15% to $2.561 million, from $2.221 million in the prior year period, primarily due to a $465 thousand rise in stock-based compensation expense and a $170 thousand increase in investor relations activities, offset by a $250 thousand decrease in financial outsourced accounting fees. #### Operating Loss Operating loss was - $4.268 million for the three months ended June 30, 2026, compared to - $2.309 million for the three months ended June 30, 2025.For the six months ended June 30, 2026, the operating loss was - $8.435 million, compared to - $4.181 million for the six months ended June 30, 2025. #### Net Loss Net loss for the three months ended June 30, 2026, was - $4.138 million, compared to - $2.166 million for the same period in 2025, with the increase attributed to higher research and development expenses associated with advancing the PH-762 program.For the six months ended June 30, 2026, the net loss was - $8.141 million, compared to - $3.935 million for the six months ended June 30, 2025. #### Other Financial Metrics Total operating expenses for the three months ended June 30, 2026, were $4.268 million, up from $2.309 million in the prior year.For the six months ended June 30, 2026, total operating expenses were $8.435 million, compared to $4.181 million in the prior year.Interest income, net, was $130 thousand for the three months ended June 30, 2026, and $291 thousand for the six months ended June 30, 2026.Other income, net, was $0 thousand for the three months ended June 30, 2026, and $3 thousand for the six months ended June 30, 2026.Total assets as of June 30, 2026, were $14.307 million, down from $21.487 million as of December 31, 2025.Total liabilities as of June 30, 2026, were $1.705 million, up from $1.340 million as of December 31, 2025.Total stockholders’ equity as of June 30, 2026, was $12.602 million, down from $20.147 million as of December 31, 2025. #### Outlook / Guidance Phio Pharmaceuticals Corp. expects its existing cash and cash equivalents to fund planned operations into the second half of 2027.Management anticipates that research and development expenses will continue to increase as the PH-762 program advances.The company plans to request an FDA meeting in the third quarter of 2026 to discuss next steps in the clinical trial design and development strategy for PH-762. ### Related Stocks - [PHIO.US](https://longbridge.com/en/quote/PHIO.US.md) ## Related News & Research - [Phio Pharma wins U.S. patent allowance for BRD4-targeting INTASYL compound PH-894](https://longbridge.com/en/news/295525767.md) - [Phio net loss widens to $4.14 million in Q2 FY26](https://longbridge.com/en/news/295141049.md) - [Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026 | PHIO Stock News](https://longbridge.com/en/news/282184588.md) - [03:07 ETHot off the Press: Recent Publications from Improved Pharma and Varda Space Industries Collaboration](https://longbridge.com/en/news/285165527.md)